Payment overview · 2025
General Payments
$1,443.33
39 reported records · 12 companies
Healthcare provider profile · identity verified
Eileen Beale, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · TOWSON, MD · NPI 1679977276
Verified facts
What the public records show
CMS Open Payments records show Eileen Beale, NP received $1,443.33 in general payments during 2025 across 39 reported records.
AstraZeneca Pharmaceuticals LP accounted for 21.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Paxlovid, Rybelsus.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $312.64 | 21.7% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $300.11 | 20.8% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $230.50 | 16.0% | 7 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $137.86 | 9.6% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $115.75 | 8.0% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $115.19 | 8.0% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $81.90 | 5.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $52.38 | 3.6% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $31.84 | 2.2% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $25.57 | 1.8% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $21.94 | 1.5% | 1 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $17.65 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,443.33 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $300.11 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $230.50 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $209.53 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $147.74 | 6 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $137.86 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $115.19 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $82.68 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $81.90 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $75.59 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $75.59 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $52.38 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $50.09 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $37.25 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $31.84 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $25.57 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $21.94 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $20.13 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $20.13 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $20.13 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $20.03 | 1 | 2025 |
Source payment records
|
|||||
| Dyanavel XR Normalized: dyanavel xr |
Drug | Tris Pharma Inc | $17.65 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 51 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 15 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
50 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 187 | 56 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 153 | 50 |
| Levothyroxine Sodium | Levothyroxine Sodium | 135 | 35 |
| Losartan Potassium | Losartan Potassium | 112 | 35 |
| Lisinopril | Lisinopril | 111 | 34 |
| Gabapentin | Gabapentin | 97 | 25 |
| Tramadol Hcl | Tramadol Hcl | 87 | 25 |
| Amlodipine Besylate | Amlodipine Besylate | 80 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 78 | 25 |
| Sertraline Hcl | Sertraline Hcl | 77 | 19 |
| Metformin Hcl Er | Metformin Hcl | 69 | 23 |
| Methylprednisolone | Methylprednisolone | 68 | 55 |
| Montelukast Sodium | Montelukast Sodium | 68 | 23 |
| Omeprazole | Omeprazole | 59 | 23 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 56 | 11 |
| Metoprolol Succinate | Metoprolol Succinate | 53 | 17 |
| Ozempic | Semaglutide | 51 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 51 | suppressed |
| Jardiance | Empagliflozin | 50 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 50 | 17 |
| Bupropion Xl | Bupropion Hcl | 45 | 14 |
| Famotidine | Famotidine | 42 | 15 |
| Simvastatin | Simvastatin | 42 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 39 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 39 | 17 |
| Alprazolam | Alprazolam | 38 | 18 |
| Azelastine Hcl | Azelastine Hcl | 38 | 19 |
| Metformin Hcl | Metformin Hcl | 38 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 38 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 37 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 37 | 28 |
| Glimepiride | Glimepiride | 37 | suppressed |
| Meloxicam | Meloxicam | 37 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 37 | 12 |
| Trazodone Hcl | Trazodone Hcl | 37 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | 15 |
| Furosemide | Furosemide | 34 | 16 |
| Carvedilol | Carvedilol | 33 | suppressed |
| Prednisone | Prednisone | 32 | 22 |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 29 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 29 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 28 | suppressed |
| Clonazepam | Clonazepam | 27 | 12 |
| Alendronate Sodium | Alendronate Sodium | 26 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 25 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 25 | 17 |
| Atenolol | Atenolol | 24 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | 11 |
| Ezetimibe | Ezetimibe | 22 | suppressed |
| Lorazepam | Lorazepam | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Mupirocin | Mupirocin | 20 | 16 |
| Rybelsus | Semaglutide | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Azithromycin | Azithromycin | 16 | 16 |
| Eliquis | Apixaban | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Fluconazole | Fluconazole | 15 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Cefdinir | Cefdinir | 14 | 14 |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 11 |
| Potassium Chloride | Potassium Chloride | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | 11 |
| Prevalite | Cholestyramine | 12 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,443.33 · 39 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, BREZTRI, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, Dyanavel XR, FARXIGA, GEMTESA, Kerendia, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, REPATHA, Rybelsus, Veozah, XIFAXAN, ZAVZPRET | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error